Thermo Fisher Scientific Opens New UK Facility for Cancer Diagnostics and Chromatography Products
News Feb 11, 2010
Thermo Fisher Scientific Inc. has announced the official opening of its new facility in Runcorn, Cheshire. The new facility, located at Tudor Road, Manor Park, is a significant investment for Thermo Fisher Scientific in the North of England and is a new designated Center of Excellence for its Anatomical Pathology business.
The new facility is said to be the largest Thermo Fisher Scientific center in the North of England and one of its biggest in the United Kingdom. Thermo Fisher manufactures products used daily in hospitals and laboratories around the world, helping doctors treat patients and scientists advance human knowledge.
Thermo Fisher chose the Northwest of England as home for the new facility due to the strength of the region’s academic, hospital, pharmaceutical and biotechnology industry sectors.
The new facility has created approximately 60 new jobs, and the total workforce onsite is now more than 200. UK Trade and Investment worked closely with the North West Regional Development Agency to ensure that Thermo Fisher’s requirements were met.
The new facility houses Thermo Fisher’s Anatomical Pathology and Chromatography Consumables businesses. This includes products and services to improve the detection and diagnosis of cancer and advance research for drug development. In 2009, Thermo Fisher Scientific consolidated operations from locations in California and Eastbourne, UK to Runcorn.
The facility’s R&D Director has relocated from the U.S. to oversee product development. The Anatomical Pathology business is positioned to serve the need for new and more effective diagnostic technologies and treatments as cancer rates increase around the world.
The new facility is also a manufacturing center for Thermo Fisher’s Chromatography Consumables business. These products are used in laboratories specializing in chromatography and mass spectrometry analysis. They enable detection, quantification and isolation of complex sample mixtures that are commonly encountered in pharmaceutical, environmental, biomedical, chemical, toxicology, forensics and food safety industries.
The new facility was officially opened by Dr. Yuh-geng Tsay, president, Specialty Diagnostics and Dr. Roger Platt, chairman, Northwest Science Council. The ceremony also included presentations by Steven Broomhead, chief executive, NWDA and Thermo Fisher Scientific customers.
Research Team Discovers Compound that Stops Cancer From SpreadingNews
Using a mouse model, OHSU physician-scientists lead effort to hone a drug that inhibits cancer cells from spreading to other areas in the body.READ MORE
PhoreMost and o2h Discovery Collaborate to Progress First-in-Class Drug Discovery ProgramsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has entered into a collaboration with o2h discovery (o2h), an Anglo-Indian medicinal chemistry company that has in-house capability to take drug discovery programmes to the IND filing stage.READ MORE
Penn Medicine Biochemist Receives Major Award for Research on Epigenetic Protein Modifications via Mass SpecNews
Benjamin A.Garcia, PhD, an expert in quantitative proteomics and Presidential Professor of Biochemistry and Biophysics in the Perelman School of Medicine at the University of Pennsylvania, has been awarded the Biemann Medal by the American Society for Mass Spectrometry (ASMS). The early-career award recognizes significant achievement in basic or applied mass spectrometry.